Surgical outcomes were improved by the introduction of the operative microscope in the 1960s and perioperative care utilizing induced hypertension, hypovolemia, and hemodilution ("HHH therapy").
Improved outcome derived in part by the introduction of effective regimens in genetically defined "high-risk" disease (i.e., 17p−, 11q−, TP53, NOTCH1, SF3B1 mutations), especially in the younger and/or fit patients.
Nevertheless, many attempts have been undertaken to improve the outcome of these patients by the introduction of new chemotherapeutic agents, the use of alternating drug combinations, high-dose chemotherapy schedules or chemotherapy schedules that apply drugs at high density (Table 1).
However, the estimated hospital outcome rates were weakly affected by the introduction of clinical data and drug prescription information.
It would appear likely, then, that early detection of impaired glycometabolic control might improve outcome by allowing introduction of secondary preventative measures.
Improved outcome in CLL derived in part by the introduction of novel regimens which proved to be effective in all risk categories, including genetically defined "high-risk" disease (i.e., 17p−, 11q−, TP53, NOTCH1, SF3B1 mutations).
The interest in this type of technique, which is based on the assumption that AC joint reduction and anatomical restoration provide more satisfactory outcomes [16], has recently been revived by the introduction of synthetic ligaments [17, 18] and biological grafts [16, 19].
This outcome indicates that the introduction of intelligence in the mobile devices eases their proactive management.
Outcome measures were the introduction of new multidisciplinary therapies and survival.
8 29 Perinatal outcomes after the introduction of the Finnish intervention were evaluated in three studies.
